Long Noncoding RNAs in Lung Cancer: From Disease Markers to Treatment Roles

Lin Chen1,2,*, Yuxin Xie1,3,*, Min Yu2, Qiheng Gou1

1Department of Head and Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China; 2Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China; 3Laboratory of Molecular Diagnosis of Cancer, Clinical Research Center for Breast, West China Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China

*These authors contributed equally to this work

Abstract: There is an urgent need to identify reliable biomarkers that can be used in early diagnosis, prognostication prediction and as possible therapeutic targets for lung cancer due to its current poor prognosis. Long noncoding RNAs (lncRNAs) have recently attracted additional attention due to their potential role in carcinogenesis, invasion and metastasis. Issues involved in the biofunctions and regulatory mechanisms of oncogenic and tumor-suppressive lncRNAs in lung cancer are discussed. Some lncRNAs have shown good diagnostic value, especially in combination with conventional serum protein markers. The use of antisense oligonucleotides, small molecules and RNA interference techniques have shown promise as direct therapeutic tools for targeting lncRNAs in preclinical studies. The biomarker function of lncRNAs may also indirectly involved in tumor therapy as a reference to conventional therapy. Overall, the concept of using lncRNAs as biomarkers for prognostication and intervention in lung cancer is still in its infancy, and only with more in-depth studies could they have a significant impact.

Keywords: long noncoding RNAs, biomarker, lung cancer, diagnosis, treatment

Introduction

Lung cancer is a malignant tumor that originates in the mucosa or glands of the bronchi of the lung. Globally, lung cancer is the second most frequent cancer and the leading cause of cancer death in 2020, with an estimated 2.2 million new cases (11.4% of total cases) and 1.8 million deaths (18.0% of total deaths).1 Although the introduction of immune checkpoint inhibitors (ICIs) has fundamentally transformed the treatment of lung cancer, the 5-year overall survival rate remains low, rarely exceeding 30%.2

Noncoding ribonucleic acids, which comprise more than 97% of the human genome, have a variety of physiological and pathological functions and they play a major role in lung cancer tumorigenesis.3 Furthermore, noncoding ribonucleic acids can be divided into short and long noncoding RNAs (lncRNAs). LncRNAs are extensively involved in biological processes such as gene expression, cell differentiation, organogenesis and homeostasis in human tissues. In recent years, lncRNAs have drawn extra attention for their role in human hematological or solid malignancies. More than 95% of the articles retrieved from PubMed on lncRNAs and lung cancer were published after 2017.

Although current targeted therapies for lung cancer have relatively high response rates, the inevitability of treatment resistance and the rarity of driver mutations in squamous and small cell lung cancers limit the efficacy of targeted therapies and the prognostic value of driver mutation detection. To find new therapeutic and diagnostic targets, additional molecular pathways must be explored and investigated. LncRNAs may be potential candidates for this purpose.

In this article, we reviewed the role of lncRNAs in diagnosis, treatment response monitoring and prognostication of lung cancers.
An Overview on lncRNAs

LncRNAs are nonprotein-coding RNAs of more than 200 nucleotides and can be loosely defined as transcripts that carry out their functions as RNA molecules and do not belong to any other class of small or structural RNA molecules. LncRNAs can be categorized into six groups based on the genomic localization of the nearest protein-coding gene, namely, (a) sense, (b) antisense, (c) bidirectional (d) intronic, (e) intergenic and (f) enhancer lncRNAs. Similar to messenger RNAs, lncRNA expression is also regulated transcriptionally and epigenetically. Unlike protein-coding genes, a higher density of DNA methylation around their transcription start sites has been observed, suggesting they play an important role in the epigenetic regulatory network. LncRNAs are usually transcribed by RNA polymerase II and their posttranscriptional processing is similar to that of protein-coding genes, including alternative splicing, 5′-capping, and polyadenylation. The diversity of lncRNAs helps explain the developmental complexity of higher evolved organisms and demonstrates their important functional role in biological processes by interacting with chromatin, interacting with RNA targets, and regulating proteins. LncRNAs are also involved in various posttranscriptional modifications, including phosphorylation and ubiquitination.

LncRNAs in Lung Cancer

Although many new lncRNAs have been identified by current screening methods, their functional characteristics need to be experimentally demonstrated. Only a few validated and well-characterized lncRNAs have been reported to be deregulated and functional in lung cancer, as summarized in Table 1.

Oncogenic lncRNAs

Oncogenes are genes whose encoded products can promote tumorigenesis and progression. Multiple oncogenic lncRNAs, such as metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), HOX transcript antisense RNA (HOTAIR) and H19, promote the growth, proliferation and invasion of lung cancer.

MALAT1

MALAT1, also known as noncoding nuclear-enriched abundant transcript 2 (NEAT2), is a highly abundant and conserved nuclear lncRNA. MALAT1 is involved in many types of physiological processes, such as alternative splicing, nuclear organization, epigenetic regulation of gene expression, and pathological processes, ranging from diabetes complications to cancers. As one of the first identified cancer-associated lncRNAs, MALAT1 has been found to have prognostic value in different types of tumor models, including non-small-cell lung cancer (NSCLC), renal clear cell carcinoma, pancreatic cancer and hepatocellular carcinoma (HCC).

In NSCLC, MALAT1 is highly expressed in primary tumors and tumors overexpressing it have a higher tendency to metastasize. Highly efficient knockdown of MALAT1 using zinc finger nuclease-based technology confirmed that MALAT1 promotes metastasis in vitro and in vivo without affecting cell proliferation. Conversely, the use of antisense oligonucleotides (ASOs) inhibits metastasis formation by reducing the expression level of MALAT1 in tumors and surrounding stromal

Table 1 Summarization of Discussed lncRNAs

<table>
<thead>
<tr>
<th>LncRNA</th>
<th>Chromosome Location</th>
<th>Expression Level</th>
<th>Clinical Association</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>MALAT1</td>
<td>11q13</td>
<td>Upregulation</td>
<td>Metastasis and short overall survival</td>
<td>[18]</td>
</tr>
<tr>
<td>HOTAIR</td>
<td>12q13.13</td>
<td>Upregulation</td>
<td>Advanced stage, poor prognosis and drug resistance</td>
<td>[35–39,42]</td>
</tr>
<tr>
<td>H19</td>
<td>11p15.5</td>
<td>Upregulation</td>
<td>Advanced stage, tumor size and short overall survival</td>
<td>[54]</td>
</tr>
<tr>
<td>MEG3</td>
<td>14q32.2</td>
<td>Downregulation</td>
<td>Inhibiting invasion and regulating chemoresistance</td>
<td>[58–60]</td>
</tr>
<tr>
<td>GASS</td>
<td>1q25.1</td>
<td>Downregulation</td>
<td>Inhibiting proliferation, migration, invasion and promoting apoptosis</td>
<td>[69,72]</td>
</tr>
<tr>
<td>SPRY4-IT1</td>
<td>5q31.3</td>
<td>Downregulation</td>
<td>Inhibiting tumor cell growth, migration, invasion and EMT</td>
<td>[74]</td>
</tr>
</tbody>
</table>
Furthermore, MALAT1 enhances the brain metastatic potential of lung cancer by regulating the epithelial-to-mesenchymal transition (EMT) process. Additionally, in a lung cancer homing model, MALAT1 and gene knockout reduced the possibility of lung cancer cells homing to the lung. The function of MALAT1 is regulated by multiple signaling pathways in tumor proliferation, invasion and metastasis.

The mode of action of MALAT1 is currently speculated to be multifaceted, including transcription and/or premRNA splicing of critical genes involved in migration and cell adhesion, as well as genes involved in critical cancer pathways. MALAT1 regulates the activity of serine/arginine (SR) splicing factors, thereby affecting gene expression through alternative splicing. In a normal human diploid fibroblast cell line, MALAT1 deprivation resulted in a proliferation defect, attributed in part to changes in alternative splicing of mitotic regulators such as transcription factor B-MYB. Moreover, MALAT1 is involved in the regulation of the cell cycle. The interaction of MALAT1 with nuclear heterogeneous nuclear ribonucleoprotein C (hnRNP C) is essential to promote hnRNP C translocation to the cytoplasm during G2/M phase. In addition, MALAT1 is also involved in the epigenetic control of gene expression by acting as a subnuclear molecular scaffold that specifically localizes unmethylated polycomb protein 2 to promote gene activation between chromatin bodies.

Despite the diverse functions and high conservation of MALAT1, MALAT1 knockout mice are viable and fertile, with no defects in gene expression, SR splicing factor activity, or alternative splicing levels. Thus, MALAT1 emerges as a potential target for preventing metastasis in lung cancer.

### HOTAIR

HOTAIR is transcribed in the antisense direction from chromosome 12 between HOXC11 and HOXC12. Sequence analysis of HOTAIR showed that it is present in mammals with poorly conserved sequences but a reasonably conserved structure. HOTAIR conserved sequences predate whole genome duplication events in vertebrate roots, with evidence that HOTAIR has 32 nucleotide-long conserved noncoding elements (CNEs) similar to those in the HOXD cluster region.

HOTAIR is thought to function as a modular scaffold due to its 5′ and 3′ structural domains interacting with polycomb repressive complex 2 (PRC2) and lysine-specific demethylase 1 (LSD1), respectively. By interacting with PRC2, HOTAIR triggers histone 3 lysine 27 (H3K27) trimethylation of the HOXD locus on human chromosome 2, which modulates the chromatin state. Additionally, since LSD1 is part of the RE1-silencing transcription factor CoREST-REST repressor complex, the interaction of the 3′ structural domain of HOTAIR with LSD1 will lead to the demethylation of the H3K4me2 histone mark near the transcription start site of the HOXD gene, resulting in epigenetic regulation of HOXD gene transcription.

HOTAIR is highly expressed in most tumors, including breast cancer, HCC, colorectal cancer, gastric cancer and NSCLC. High HOTAIR levels are associated with advanced or metastic disease and a poor prognosis. In NSCLC, 22.1% of patients show at least a 2-fold increase in HOTAIR expression, and the more advanced the stage, the higher the fold increase. Reduced invasive and metastatic potential of cancer cells was observed in vivo and in vitro assays through siRNA-mediated downregulation of HOTAIR. Studies further confirm that HOTAIR mediates its prometastatic and proinvasive functions by regulating the levels of matrix metalloproteinase 2 (MMP2), MMP9 and homeobox protein A5 (HOXA5) proteins but not EMT-promoting proteins. In addition to its prometastatic function, high expression of HOTAIR leads to resistance to cisplatin by downregulating CDKN1A in a lung adenocarcinoma model. In terms of targeted therapy, downregulation of HOTAIR increases the sensitivity of NSCLC cell lines to crizotinib by inhibiting the phosphorylation of ULK1. Similar to NSCLC, in small cell lung cancer (SCLC), downregulation of HOTAIR can improve the sensitivity of SCLC to cisplatin, Adriamycin and etoposide by reducing the expression of DNA methyltransferase 1 and 3B.

In summary, HOTAIR is involved in gene regulation and tumor metastasis processes and is significantly associated with a poor prognosis and treatment resistance in cancer. Therefore, it has a high biomarker potential. In the future, with more detailed studies about the regulation and mode of action of HOTAIR, it may become a therapeutic target for tumors.
**H19**

H19 is a paternally imprinted gene localized on human chromosome 11p15 that is only transcribed from the maternally inherited allele. H19 was originally named ASM because it is expressed in adult skeletal muscle (“ASM”) of rats. Mineral dust and tobacco smoke are well-known carcinogens, both of which can increase the expression level of H19 through epigenetic changes, further contributing to the poor prognosis of lung cancer. H19 is known to have oncogenic effects in several cancers, such as hepatocellular carcinoma, bladder cancer, breast cancer, gastric cancer, colorectal cancer and lung cancer. In NSCLC, H19 induces cell proliferation, migration, survival, invasion and EMT while reducing apoptosis.

In NSCLC, the expression level of H19 is significantly increased, which impairs the inhibitory effect of miR-138 on PDK1 protein expression, resulting in decreased miR-138 and enhanced cell proliferation ability. Similarly, overexpression of H19 inhibits the function of miR-200a, thereby upregulating the miR-200a targeted genes ZEB1 and ZEB2, which enhanced the proliferation and metastasis of lung cancer. LncRNA H19/miR-29b-3p/STAT3 signaling is involved in the EMT process in lung adenocarcinoma.

Studies have confirmed that hypoxia is a major inducer of H19. Thus, H19 functions as a stress modulator and survival factor and is involved in several essential processes triggered by hypoxia. In lung cancer cells, H19 is induced in a p53-dependent manner. Reconstitution of wild-type p53 in lung cancer cells with null p53 mutations eliminated the induction of H19 by hypoxia. For lung cancer cells possessing wild-type p53, both inhibition of p53 and overexpression of HIF1-α are required to significantly upregulate H19 in response to hypoxia.

In the clinical setting, by using quantitative reverse transcription PCR (qRT–PCR) to detect H19 expression in tumor tissues and corresponding nontumor NSCLC tissues of 70 patients, it was found that high H19 expression was positively correlated with advanced stage and tumor size. Multivariate analysis revealed that H19 expression could be an independent prognostic factor for overall survival in NSCLC. In therapeutic applications, approaches have targeted different cancer-specific transcriptional products of H19 or used their transcriptional regulatory elements to drive the expression of cytotoxic genes, specifically targeting tumor cells. These would have a key advantage over current conventional therapeutic agents, as they could spare normal cells.

In summary, H19 is considered to be a biomarker of cancer and a potential therapeutic target for these human diseases, but further investigations are necessary required.

**Tumor-Suppressive lncRNAs**

Multiple tumor suppressor lncRNAs, such as maternally expressed gene 3 (MEG3), growth arrest-specific transcript 5 (GAS5), and sprouty 4 intronic transcript 1 (SPRY4-IT1), are downregulated in NCSLC, thereby promoting the development and progression of NSCLC.

**MEG3**

MEG3 is a maternally expressed, imprinted lncRNA located on chromosome 14q32.3. MEG3 acts as a growth suppressor in tumor cells and activates p53.

A reduction or loss of MEG3 expression has been observed in various cancers, including lung cancer, and its lower expression level is associated with advanced stage and poor outcome. MEG3 was found to be decreased in lung cancer stem cells, reducing its suppression of migration and invasion. Moreover, overexpression of MEG3 contributes to restoring the sensitivity of tumor cells to chemotherapy by inhibiting cell differentiation, inducing apoptosis and reducing autophagy, both in vivo and in vitro. MEG3 overexpression also leads to reduced expression of N-cadherin, vimentin, snail-1, and -catenin, thereby decreasing EMT.

In most cases, MEG3 dysregulation is due to copy number loss of 14q32 or CpG hypermethylation in functionally critical genomic regions upstream of the MEG3 gene, which further inhibits the p53 pathway. MEG3 interacts with the transcription factor c-Jun, which inhibits PHLPP1 transcription and leads to activation of the Akt/p70S6K/S6 axis and translation of the HIF1-α protein, thus exerting a tumor suppressive effect.
Due to its prognostic properties and tumor suppressor function, MEG3 could theoretically serve as a marker of prognosis or therapeutic response or even be a target for tumor therapy. In gliomas, the DNA methylation inhibitor 5-aza-2'-deoxycytidine (5-azadC) reduced the abnormal hypermethylation of the MEG3 promoter and prevented the hypoexpression of MEG3. However, more studies on the role of MEG3 in lung cancer are necessary.

GAS5
GAS5 was originally identified by Schneider from a cDNA library enriched for RNA sequences in growth arrested mouse fibroblasts and was found to be located on human chromosome 1q25. The structure and biological function of GAS5 is conserved in mice and humans. GAS5 expression is increased during growth arrest, making the cells sensitive to apoptosis inducers. Further study revealed that GAS5 could bind competitively to glucocorticoid response elements on DNA, thus preventing the activation of glucocorticoid response genes and reducing cellular metabolism, growth arrest, and apoptosis sensitization. Due to its physiological role in growth arrest and apoptosis, GAS5 also has a tumor suppressive role and its expression is downregulated in a variety of tumors, including lung cancer. GAS5 mechanism shows that ectopic overexpression of GAS5 increases the protein levels of P53 and P21 and decreases the expression of E2F1. From a clinical point of view, since GAS5 levels are correlated with patient survival, they can be used as a prognostic marker and efficacy predictor for a variety of tumors. The regulatory mechanisms of GAS5 in inhibiting cell proliferation and promoting apoptosis offer the possibility of pharmacological intervention. GAS5 antitumor effects could theoretically be exerted either by drug-induced expression of endogenous GAS5 or by expression of RNA containing GAS5’s functional domain.

SPRY4-IT1
SPRY4-IT1 is located within the second intron of the SPRY4 gene on chromosome 5q31. SPRY4 acts as an inhibitor of the MAPK signaling pathway, which acts in the upstream pathway of RAS activation and inhibits the formation of GTP-RAS. SPRY4-IT1 acts as a tumor suppressor in lung cancer by inhibiting tumor cell growth, migration, invasion and EMT. SPRY4 mRNA and protein levels are decreased in lung cancer cell lines. Of clinical importance, patients with low SPRY4-IT1 expression have a worse prognosis than those with relatively high expression. It has been demonstrated that SPRY4-IT1 is negatively correlated with the expression of EZH2, a core subunit of PRC2. In lung adenocarcinoma cell lines, EZH2 promotes H3K27 trimethylation by binding to the promoter of SPRY4-IT1, which in turn downregulates SPRY4-IT1 expression. It has also been found that knockdown of SPRY4-IT1 results in downregulation of EMT-related e-cadherin expression and upregulation of vimentin expression. Thus, EZH2 overexpression promotes invasion and migration of lung adenocarcinoma cells by suppressing SPRY4-IT1 expression. Interestingly, unlike in lung cancer, SPRY4-IT1 is upregulated and exerts tumor-promoting effects in a variety of tumors, including melanoma, ovarian, bladder, and colorectal cancers. Thus, SPRY4-IT1 downregulation may be a specific biomarker for lung cancer patients.

Overall although some lncRNAs have shown potential as markers for predicting disease staging and metastasis and assessing patient prognosis, there are still many obstacles to the application of lncRNAs in the clinical setting. On the one hand, preclinical experiments have shown some results, but many lncRNAs are primate/human-specific and cannot be studied in mice. Additionally, even though altered expression of lncRNAs has been determined to be associated with various tumors, it is not yet clear whether the alterations are a cause or a consequence of the disease; thus, a comprehensive understanding of the structure, mechanisms, intermolecular interactions of lncRNAs and the development of new quantitative analytical screening drugs is needed.

LncRNA-Based Diagnostics and Therapies in Lung Cancer
Lung cancer is a malignancy with a very poor prognosis and a low 5-year overall survival rate, mainly due to late diagnosis and rapid development of treatment resistance. There is an immediate need for new highly sensitive, specific, stable, easily and rapidly detectable biomarkers. LncRNA detection is facilitated due to its stability and ease of obtaining...
it from plasma or other body fluids. Second, since the expression of multiple lncRNAs is altered during tumor formation, lncRNAs can be used in combination approaches to establish more reliable diagnostic and prognostic models.81 Taken together, lncRNAs hold promise as ideal biomarkers.

**LncRNAs in Lung Cancer Diagnosis**

Due to the lack of stable and reliable biomarkers, many patients are currently diagnosed at an advanced stage. Difficulty in early diagnosis is the main reason for the poor prognosis of lung cancer. In the past, serum proteins such as CEA and CYFRA21-1 have been the main targets of tumor biomarker research, but their diagnostic applications are still limited. With in-depth research on the mechanism and functions of lncRNAs, there is increasing interest in the role of lncRNAs in early diagnosis.

Since circulating lncRNAs are contained within lipid or lipoprotein vesicles (eg, apoptotic cells, exosomes, or microvesicles), they exhibit high stability even under repeated freezing and thawing, incubation at 45°C for 24 hours, incubation at room temperature for 24 hours, and other harsh conditions.82,83 Current studies have confirmed that multiple lncRNAs are aberrantly expressed in NSCLC. The most fully evaluated candidate blood biomarker for NSCLC diagnosis is MALAT1.84 The expression of MALAT1 is downregulated in blood samples from NSCLC patients compared to those from healthy volunteers, with a sensitivity of 56% and a specificity of 96% as a lung cancer diagnosis marker.85 Moreover, the expression level of MALAT1 is also correlated with the presence of metastasis and the sites of metastatic lesions.85,86 However, the diagnostic value of MALAT1 alone is limited by the lack of significant differences in MALAT1 expression between adenocarcinoma and squamous cell carcinoma and the low diagnostic sensitivity of MALAT1 alone.85,87 Simultaneous detection of multiple lncRNAs can improve the sensitivity and specificity of the diagnosis.88 Similarly, serum GAS5 expression is significantly decreased in NSCLC patients compared with healthy volunteers, and it has a sensitivity of 82.2% and specificity of 72.7% as a marker to distinguish patients with lung cancer. When combined with CEA levels, the sensitivity and specificity are improved.89

In a recent study, 84 dysregulated lncRNAs in lung cancer were identified by comparing RNA sequencing data with TCGA data, among which 10 lncRNAs were meaningfully associated with patient survival. LINC01537 was considered the most important and its downregulation was verified in a validation analysis.90

**LncRNAs in Lung Cancer Treatment**

The clinical value of lncRNAs is not limited to their biomarker potential; they also have therapeutic aspects. LncRNAs are key regulators of many physiological and pathological processes, and they play a role in the regulation of gene expression and molecular pathways through interactions with proteins, miRNAs and other factors. Thus, lncRNAs may be a potential target for cancer treatment in the future.91 Targeting lncRNA therapy will be highly dependent on the function of lncRNAs, where advances in technologies offer the possibility of selectively targeting the expression of lncRNAs.92,93 For oncogenic lncRNAs, reducing their expression or affecting their functions can restore the sensitivity of cancer cells to antitumor therapy, inhibit the ability of cancer cells to invade and metastasize, or even achieve a cure for tumors. For example, inhibition of MALAT1 and HOTAIR expression in vivo by ASO effectively reduced metastasis and cancer cell migration or invasion in mice.25,94 Small-molecule inhibitors have provided us with another approach to regulate lncRNAs with the advantages of good solubility, bioavailability and metabolic stability compared to ASOs. Small molecule inhibitors target lncRNA-protein interactions by directly interfering with the secondary structure of lncRNAs or by masking the binding sites of their interactors.95–98 However, this approach requires a better understanding of RNA-protein interactions. Another direction is to use RNA interference-mediated gene silencing to selectively silence oncogenic lncRNAs.99,100 For tumor suppressor lncRNAs, there is currently no defined therapeutic targeting method, and in general, increasing their expression or enhancing their effects should be the direction of exploration. Approaches targeting lncRNAs are summarized in Table 2. Tumor progression was conspicuously impeded in triple-negative breast cancer and esophageal squamous cell carcinoma when siRNA nanoparticles were systematically administered in mouse model.101,102 Off-targeting is, however, now a major challenge for siRNAs.

Overall, many common challenges remain in the development of directly targeting lncRNA therapy, including the lack of safe, specific and effective delivery methods, the absence of a defined optimal dosing regimen and the prevention
of off-targeting. Although most of the researches on lncRNAs are still in the preclinical stage, researches on mitochondrial long non-coding RNA (mtlncRNA) have progressed rapidly and some are already in clinical trials. For example, a phase Ia trial evaluating Andes-1537, a short single-chain ASO, for the treatment of patients with advanced solid tumors (NCT02508441). The results showed that Andes-1537 was well tolerated, with no dose-limiting toxicities observed except for two injection site reactions in the high-dose group, and potential antitumor effects, with 2 patients (11.8%) had stable disease on scans beyond six months.

Following the preliminary signals of efficacy observed in phase Ia trial, an open, multicentric, two stage phase Ib trial (NCT03985072) was initiated to investigate the safety and tolerability of the drug in cancer patients from 6 cohorts, associated to six different cancer type.

In addition to directly targeting lncRNA therapy, lncRNAs such as HOTAIR and H19 and their roles in tumor staging can also be used as biomarkers for reference in conventional therapy and patient monitoring. Gong et al evaluated the association between polymorphisms of some lncRNAs, the lung cancer risk and the patient response to treatment modalities in a Chinese population. Among them, polymorphisms of H19, MALAT1 and HOTAIR were associated with the patient response to platinum-containing chemotherapy. Subgroup analysis showed that ANRIL polymorphisms were associated with the response to platinum-based chemotherapy in adenocarcinoma patients, while ANRIL and H19 polymorphisms were associated with the treatment response in SCLC patients. In addition, polymorphisms within lncRNAs have been associated with the toxicity of platinum-based chemotherapy. For example, ANRIL polymorphisms are associated with severe overall toxicity and severe gastrointestinal toxicity, and MEG3 polymorphisms are associated with severe gastrointestinal toxicity.

We have listed several lncRNAs that are the most promising for clinical use in lung cancer and their possible regulatory mechanisms. However, there are far more aberrant lncRNAs in lung cancer. Our previous study showed that LINC00460 is significantly upregulated and acts as an oncogene in NSCLC and is associated with a poor prognosis. Further study revealed that LINC00460 is involved in cell migration and invasion through physical interactions with hnRNP K. We also identified and characterized a fusion circRNA (F-circEA) produced from EML4-ALK-positive NSCLC that promotes cell migration and invasion. In addition, the currently discovered and validated lncRNAs can be used in combination, such as using lncRNAs+lncRNAs and lncRNAs+proteins, to form detection kits to improve their clinical value.

### Table 2: Examples of Strategies in lncRNA-Based Therapies

<table>
<thead>
<tr>
<th>Approach</th>
<th>Mechanism</th>
<th>Target lncRNA</th>
<th>Disease</th>
<th>Impact</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASO</td>
<td>Specifically bind to targeted RNAs then activate RNase H or selectively promote expression of a certain spliceosome</td>
<td>MALAT1</td>
<td>NSCLC</td>
<td>Inhibition of lung metastasis in mice</td>
<td>[25]</td>
</tr>
<tr>
<td></td>
<td>Select specific compounds by microarray and molecular docking technology based on scaffold-based small molecule libraries</td>
<td>HOTAIR</td>
<td>NSCLC</td>
<td>Reduced cell migration and invasion</td>
<td>[94]</td>
</tr>
<tr>
<td></td>
<td>Specifically interfering HOTAIR/EZH2 interaction</td>
<td>MALAT1</td>
<td>-</td>
<td>-</td>
<td>[95]</td>
</tr>
<tr>
<td></td>
<td>One-bead-two-compound screening strategy identifying NP-C86</td>
<td>HOTAIR</td>
<td>BC</td>
<td>Inhibiting tumor metastasis</td>
<td>[96]</td>
</tr>
<tr>
<td></td>
<td>Inducing lncRNA downregulation</td>
<td>GASS</td>
<td>Diabetes</td>
<td>Increased glucose uptake in adipocytes</td>
<td>[97]</td>
</tr>
<tr>
<td>Small molecule</td>
<td>Select specific compounds by microarray and molecular docking technology based on scaffold-based small molecule libraries</td>
<td>HULC</td>
<td>ES</td>
<td>Phase 1/2 trial shows encouraging early evidence of anti-tumor activity in heavily pre-treated patients</td>
<td>[98]</td>
</tr>
<tr>
<td>RNA interference</td>
<td>Transfecting with MALAT1-specific shRNA expression plasmids</td>
<td>MALAT1</td>
<td>MM</td>
<td>Inhibited proliferation</td>
<td>[99]</td>
</tr>
<tr>
<td></td>
<td>siRNA recruits RISC to induce lncRNA degradation</td>
<td>LINC01296</td>
<td>NSCLC</td>
<td>Inhibited proliferation, accelerated apoptosis</td>
<td>[100]</td>
</tr>
<tr>
<td></td>
<td>Transfecting with MALAT1-specific shRNA expression plasmids</td>
<td>MALAT1</td>
<td>MM</td>
<td>Inhibited proliferation</td>
<td>[99]</td>
</tr>
<tr>
<td></td>
<td>siRNA recruits RISC to induce lncRNA degradation</td>
<td>LINC01296</td>
<td>NSCLC</td>
<td>Inhibited proliferation, accelerated apoptosis</td>
<td>[100]</td>
</tr>
<tr>
<td></td>
<td>siRNA recruits RISC to induce lncRNA degradation</td>
<td>DANCR</td>
<td>TNBC</td>
<td>Suppress the invasion and proliferation</td>
<td>[102]</td>
</tr>
</tbody>
</table>

**Abbreviations:** ASO, antisense oligonucleotide; BC, breast cancer; DANCR, differentiation antagonizing non-protein coding RNA; ES, Ewing sarcoma; HULC, highly upregulated in liver cancer; MM, Multiple myeloma; NSCLC, non-small cell lung cancer; RISC, RNA-induced silencing complex; TNBC, triple-negative breast cancer.
This review also has several limitations. Briefly, with more than 3000 recent reports of lncRNAs associated with lung cancer, we have highlighted only a few types that currently appear most likely to translate into clinical applications. Second, no systematic reviews and meta-analyses have been performed to quantify the value of lncRNAs as biomarkers and therapeutic targets, especially for targeted therapies, anti-angiogenic, and immunotherapies.

**Conclusion**

LncRNAs are biomarkers with great potential. In this review, we summarize the current findings of the most important lncRNAs and their use in the diagnosis and treatment of lung cancer. There is an urgent need for early diagnosis and alternative treatment options to improve patient prognosis. LncRNAs open up a new world. However, most lncRNAs remain elusive in terms of their mechanism of action. More in-depth studies on lncRNAs are urgently needed to pave the way for rational cancer diagnosis and treatment.

**Abbreviations**

5-AzadC, 5-Aza-2'-deoxycytidine; ASO, antisense oligonucleotides; CNEs, conserved noncoding elements; GAS5, growth arrest-specific transcript 5; H3K, HOTAIR triggered histone 3 lysine; HCC, hepatocellular carcinoma; hnRNP C, heterogeneous nuclear ribonucleoprotein C; HOTAIR, HOX transcript antisense RNA; HOXA5, Homeobox protein A5; ICIs, Immune checkpoint inhibitors; LncRNAs, long noncoding RNAs; LSD1, lysine-specific demethylase 1; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed gene 3; miRNA, microRNAs; MMP, matrix metalloproteinase; NEAT2, noncoding nuclear-enriched abundant transcript 2; NSCLC, non-small-cell lung cancer; PRC2, polycomb repressive complex 2; qRT–PCR, quantitative reverse transcription PCR; SCLC, small cell lung cancer; SPRY4-IT1, sprouty 4 intronic transcript 1; SR, serine/arginine.

**Data Sharing Statement**

Not applicable to this study.

**Ethics Approval and Consent to Participate**

This report did not meet criteria for IRB approval.

**Author Contributions**

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Funding**

This work was supported by Youth Program of National Natural Science Foundation of China (81902723).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


